BeyondSpring (NASDAQ: BYSI) plans to present positive data in an abstract titled, “Quality of Life (QoL) in Advanced NSCLC Patients Treated with Docetaxel and with Either Plinabulin or Pegfilgrastim for the Prevention...
Eiger BioPharmaceuticals’ (NASDAQ:EIGR) peginterferon lambda (lambda) received FDA breakthrough therapy designation for the treatment of hepatitis delta virus (HDV) infection. HDV is the most severe form of human viral...
Zenabis Global (TSX:ZENA) signed definitive documentation for $25-million of new senior secured debt financing from R.C. Morris Capital Management. The financing involved amending and restating the debenture...
Cerecor (NASDAQ:CERC) received FDA fast track designation for CERC-802 for the treatment of mannose-phosphate isomerase deficiency, also known as CDG-1b. CDG-1b is a rare genetic disease that impacts carbohydrate...
Outlook Therapeutics (NASDAQ:OTLK) completed patient enrollment in its Phase 3 clinical trial comparing ONS-5010 to ranibizumab for the treatment of wet age-related macular degeneration (AMD). Administered via...
Myovant Sciences (NASDAQ:MYOV) completed patient recruitment for its first of two Phase 3 studies of relugolix combination therapy for the treatment of endometriosis-associated pain. Relugolix is a once daily, oral...
In a new report, GMP Securities analyst Justin Keywood gives high marks to Zenabis Global’s (TSX:ZENA) strategy for becoming a leading cannabis producer in Canada. “We see Zenabis as becoming a top-five Canadian...
Profound Medical (TSX:PRN; OTCQX:PRFMF) received FDA clearance to market TULSA-PRO for the ablation of prostate tissue, with an FDA label allowing U.S. surgeons to perform procedures on both malignant and benign tissue...
Zenabis Global (TSX:ZENA) posted second quarter gross revenue of $26.5-million, an increase of 115%, from $12.3-million in the first quarter of 2019. “We executed at or above plan in the second quarter and, in so...
Hepion Pharmaceuticals (NASDAQ:HEPA) has dosed the first hepatitis B virus (HBV) patient in a 28-day multiple ascending dose clinical trial of CRV431. The trial will assess the safety, tolerability and pharmacokinetics...
Akari Therapeutics (NASDAQ:AKTX) received FDA fast track designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients. HSCT-TMA...
Kadmon Holdings (NYSE:KDMN) completed enrollment for its registrational trial of KD025 for the treatment of chronic graft-versus-host disease (cGVHD). cGvHD is a deadly complication of hematopoietic stem cell...
Moleculin Biotech (NASDAQ:MBRX) has completed patient enrollment in its proof-of-concept trial of WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL). WP1220 is a topical treatment designed to inhibit p-STAT3...
Novan (NASDAQ:NOVN) has completed patient enrollment in its Phase 3 pivotal trial of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum. Molluscum contagiosum is a viral skin infection that...
Precipio (NASDAQ:PRPO) reported results of three key performance metrics that together demonstrate the continued growth and positive impact of the expansion of its sales force in improving pathology sales performance...
Progenics Pharmaceuticals (NASDAQ:PGNX) completed enrollment for its Phase 3 study testing the diagnostic performance and clinical impact of 18F-DCFPyL (PyL) in men with recurrent prostate cancer. PyL, a small molecule...
Kane Biotech (TSXV:KNE) received $3.8-million in funding from Western Economic Diversification Canada to assist the company in expanding from the animal health sector into the human health sector with DispersinB, a...
Eloxx Pharmaceuticals (NASDAQ:ELOX) initiated a Phase 2 trial of ELX-02 for the treatment of nephropathic cystinosis. Cystinosis is a genetic disease caused by a mutation in the cystinosin gene, which limits production...
SELLAS Life Sciences Group (NASDAQ:SLS) completed enrollment for a Phase 2 study of nelipepimut-S (NPS) in combination with granulocyte macrophage colony stimulating factor (GM-CSF) in women with ductal carcinoma in...
Mustang Bio (NASDAQ:MBIO) reported that the FDA approved its IND application for MB-102 for the treatment of acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk...
Provention Bio (NASDAQ:PRVB) received breakthrough therapy designation for PRV-031 for the prevention or delay of Type 1 diabetes (T1D) in at-risk individuals. PRV-031, an anti-CD3 monoclonal antibody also known as...
Knight Therapeutics (TSX:GUD) reached agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for a letter of intent covering reimbursement of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first...